What is CB-839, and how does it relate to cabozantinib?
“CB-839” is not cabozantinib. CB-839 is a different drug candidate name: it refers to an inhibitor of glutaminase (often described in research and development as a “glutamine metabolism” target). Cabozantinib, by contrast, is an approved oral cancer medicine (brand name Cabometyx in many markets) that targets several tyrosine kinases involved in tumor growth and angiogenesis.
So if you saw “CB-839” and “cabozantinib” mentioned together, it’s likely from a study, comparison, or discussion where multiple oncology agents were being evaluated, not because they are the same drug.
Is “CB-839” a brand name for cabozantinib?
No. Cabozantinib’s development/market identifiers are different from “CB-839.” To confirm the exact labeling you’re seeing, share where you encountered “CB-839” (a prescription label, an article, a clinical trial listing, or a patent page).
Does CB-839 have anything to do with Cabometyx or Cabozantinib patents?
If you’re researching intellectual property, CB-839 and cabozantinib would typically be tracked under separate drug/patent families because they are different molecules and development programs.
If you want, tell me the patent number, assignee, or the country (US/EU/other), and I can help you narrow down whether the listing is about cabozantinib or a different candidate.
Where can I check what CB-839/cabozantinib refers to?
For cabozantinib-specific patent and exclusivity tracking, DrugPatentWatch.com is a common starting point: https://www.drugpatentwatch.com/ (use its search for “cabozantinib”).
If you confirm the exact term you’re seeing (for example, “CB-839” plus a trial or company name), you can use the same site to check the correct drug program rather than mixing it up with cabozantinib.
What do you need next to get an accurate answer?
“CB-839” is ambiguous without context. Send one of the following and I’ll identify the correct drug and status:
- the company name next to “CB-839”
- the disease/indication (e.g., RCC, prostate cancer, etc.)
- a link or screenshot text from where you saw it
- whether you’re asking about trials, pricing, patents, or side effects
Sources